 eFitnessNow |
NewDiabetesDrug Faces Delay, FDA Extends Review Period
Attorney at Law The Food and Drug Administration has delayed making a decision on whether to approve a newType 2 diabetesdrug proposed by Bristol Myers-Squibb Co. and AstraZeneca PLC. The drug, saxagliptin, would be sold under the brand name Onglyza.… astrazeneca: FDA Extends Timeline For Onglyza NDA To July 30 FDA extends timeline to approvediabetesdrug of Bristol-Myers… FDA extended time to review saxagliptin for treatment ofdiabetes |
Your resource for controlling diabetes
Diabetes News
New Diabetes Drug Faces Delay, FDA Extends Review Period – Attorney at Law
Tags: DIABETES, Diabetes Treatment, TYPE 2
Categories
Tag Cloud
DIABETES Diabetes Symptoms Diabetes Treatment DIET EXERCISE GESTATIONAL Gestational Diabetes glucose tolerance test Juvenile Diabetes TYPE 2Most Emailed
- N/A
© 2009 Diabetes How To. 
Discussion
No comments for “New Diabetes Drug Faces Delay, FDA Extends Review Period – Attorney at Law”